Whalesbook
The GLP-1 Opportunity and OneSource's Role
OneSource Specialty Pharma is positioned at the center of a major trend and an upcoming patent expiry. The GLP-1 market is experiencing explosive growth, projected to exceed $67 billion globally in 2025. This growth is expected to accelerate as key drug patents begin to expire in 2026 across major markets like Canada, Brazil, China, and India. This shift is creating a significant manufacturing opportunity: an estimated 500 million to 1 billion additional pen devices annually, translating to a $1-2 billion market for Contract Development and Manufacturing Organizations (CDMOs) such as OneSource.
OneSource specializes in complex drug-device combinations (DDCs), manufacturing sophisticated GLP-1 injection pens. Its USFDA-approved facility in Bengaluru is key, holding rare capabilities for biologics fill-finish and device assembly within India. Recent progress includes OneSource acting as the CDMO partner for Dr. Reddy's Laboratories' generic Semaglutide Injection, an Ozempic equivalent that gained Health Canada approval on May 8, 2026. Similar recent approvals supported by OneSource in other markets highlight its role in bringing these therapies to a global commercial scale. The company is increasing its capital spending to boost cartridge capacity from 40 million units to 220 million by FY27, supported by long-term agreements with more than 20 GLP-1 customers, including major global generic manufacturers. Management reiterates its guidance for $500 million in revenue by FY28, with a target of 40% EBITDA margins, a substantial leap from its FY25 revenue of $170 million.
High Valuation vs. Growth Potential
OneSource's growth story is compelling, but its valuation is notably high compared to industry peers. As of early May 2026, the company's market capitalization is around ₹20,000-₹21,000 crore. Its trailing Price-to-Earnings (P/E) ratio is extremely high, exceeding 120x and even reaching 1000x by some measures. Normalized P/E ratios are also elevated at around 454x. This is significantly higher than established Indian CDMOs such as Syngene International, trading at approximately 57-58x P/E, and Divi's Laboratories, with a P/E around 71-72x. The broader Asian Life Sciences industry average P/E is substantially lower, around 37.7x. This premium valuation suggests the market anticipates considerable future growth, aligning with OneSource's forward-looking guidance. Based on FY28 projections of roughly ₹4,200 crore in revenue and 40% EBITDA margins, the implied forward EV/EBITDA is about 12x, which appears more attractive. The global CDMO market is strong, projected to reach $275 billion in 2026, driven by increasing outsourcing, complex biologics, and sterile injectables, with Asia Pacific being the fastest-growing region. OneSource's strong position in this growing market, focusing on high-growth areas like GLP-1s and DDCs, justifies some valuation premium. However, current trailing multiples seem stretched when compared to its own historical performance and immediate competitors.
Risks: Margin Volatility and Execution Challenges
Despite significant growth potential, OneSource faces substantial challenges. The company's valuation relies on meeting ambitious future targets, making execution crucial. While management reiterates its FY28 guidance, recent analyst sentiment has turned more cautious. Consensus revenue estimates for FY26 have fallen by 24%, and the stock price dropped 17% in the past week. A key concern is the sharp drop in Q3 FY26 EBITDA margins to 6%, down from 36% a year earlier. Although Q2 FY26 results showed 28% margins, this significant quarterly contraction suggests potential issues with margins or operations. The company's past performance is also mixed, showing flat profit growth (0% over 3 years) and negative ROE/ROCE over the last three years, contrasting with its projected strong growth. Having few major customers is a risk, as a significant portion of near-term revenue is tied to a few large GLP-1 programs. Delays in these partnerships could impact financials.
OneSource is also involved in arbitration with Prestige Biopharma Limited over a $136.32 million claim related to a vaccine manufacturing contract. This case is currently under review at the Singapore International Arbitration Centre. The potential shift to oral GLP-1 therapies could threaten its core drug-device combination business, though OneSource suggests oral contributions might be limited initially. The company's current P/E ratio, at times exceeding 1000x, highlights a gap between its current earnings and market value. This suggests a significant amount of future success is already factored into its stock price, allowing little room for error.
Analyst Views and Future Prospects
Analysts' views are generally positive, with a consensus 'Buy' rating and average 12-month price targets around ₹1,900s, indicating potential upside from its current price of about ₹1,830. However, recent analyst actions include a price target decrease and downward revisions for FY26 revenue estimates. Meeting its aggressive FY28 guidance of $500 million in revenue and 40% EBITDA margins will depend critically on successful capacity utilization, timely regulatory approvals for clients' products, and efficient management of its growing operations. The coming 12-24 months will be crucial in determining if OneSource can convert its strategic market position into sustained financial performance and justify its premium valuation, especially as it navigates the competitive CDMO landscape and evolving pharmaceutical industry demands.